跳至主要内容
临床试验/NL-OMON51027
NL-OMON51027已完成3 期

Clinical assessment of upper extremity performance in individuals with spinal cord injury using the LIFT System to deliver non-invasive electrical spinal stimulation (ARC Therapy) - The Up-LIFT Study of Non-Invasive ARC Therapy for Spinal Cord Injury

ONWARD Medical, Inc.0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • Key Inclusion Criteria:
  • Subjects must meet all the following criteria:
  • 1. At least 22 years old and no older than 75 years old at the time of
  • 2. Non-progressive cervical spinal cord injury from C2-C8 inclusive
  • 3. American Spinal Injury Association (ASIA) Impairment Scale (AIS)
  • classification B, C, or D
  • 4. Indicated for upper extremity training procedures by subject's treating
  • physician or a physical therapist
  • 5. Minimum 12 months post-injury
  • 6. Capable of providing informed consent

排除标准

  • Key Exclusion Criteria:
  • Subjects must not meet any of the following criteria:
  • 1. Has uncontrolled cardiopulmonary disease or cardiac symptoms as determined
  • by the Investigator
  • 2. Has any unstable or significant medical condition that is likely to
  • interfere with study procedures or likely to confound study endpoint
  • evaluations like severe neuropathic pain, depression, mood disorders or other
  • cognitive disorders
  • 3. Has been diagnosed with autonomic dysreflexia that is severe, unstable, and
  • uncontrolled
  • 4. Requires ventilator support
  • 5. Has an autoimmune etiology of spinal cord dysfunction/injury
  • 6. Spasms that limit the ability of the subjects to participate in the study
  • training as determined by the Investigator
  • 7. Breakdown in skin area that will come into contact with electrodes
  • 8. Has any active implanted medical device
  • 9. Pregnant, planning to become pregnant or currently breastfeeding
  • 10. Concurrent participation in another drug or device trial that may interfere
  • with this study
  • 11. Presence of syringomyelia as confirmed by an MRI
  • 12.Total baclofen dose >30 mg per day
  • 13. In the opinion of the investigators, the study is not safe or appropriate
  • for the participant

研究者

相似试验